KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy
| Autor: | Zhi-yong Chen, Jian Su, Yi-Long Wu, Hong-Hong Yan, She-Juan An, Zhimin Huang, Jin-Ji Yang, Wen-Zhao Zhong, Ji-lin Guan, Zhi-Hong Chen, Qiang Nie, Xu-Chao Zhang |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms Antineoplastic Agents Adenocarcinoma medicine.disease_cause Metastasis Proto-Oncogene Proteins p21(ras) Surgical oncology Proto-Oncogene Proteins Internal medicine medicine Carcinoma Humans Lung cancer Protein Kinase Inhibitors neoplasms Survival rate Neoplasm Staging business.industry Middle Aged Prognosis medicine.disease Small Cell Lung Carcinoma digestive system diseases respiratory tract diseases ErbB Receptors Survival Rate Drug Resistance Neoplasm Mutation Carcinoma Squamous Cell ras Proteins Cancer research Carcinoma Large Cell Biomarker (medicine) Female Surgery KRAS Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Annals of Surgical Oncology. 20:1381-1388 |
| ISSN: | 1534-4681 1068-9265 |
| DOI: | 10.1245/s10434-012-2754-z |
| Popis: | The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led to inconsistent results in previous reports. The KRAS and EGFR genes were examined in 1935 consecutive patients with non-small cell lung cancer. All patients were divided into KRAS mutation (KRAS group), EGFR mutation (EGFR group), and KRAS/EGFR wild type (WT group) groups. Randomly selected cases were paired with patients with the KRAS mutation, the EGFR mutation, and KRAS/EGFR wild type patients according to tumor, node, metastasis stage, time of first visit within 1 year, and pathology. Progression-free survival (PFS) and overall survival were evaluated by Kaplan–Meier and Cox models. The KRAS mutation rate for lung adenocarcinoma was 5.90 %. The overall survival was 14.47, 20.57, and 42.73 months for the KRAS group, WT group, and EGFR group, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink